-
The disclosure of the annual report and the first quarterly report of the pharmaceutical industry is completed, and CXO is still the focus of the industry allocation
Time of Update: 2022-05-14
In the medium and long term, according to industry prosperity indicators such as investment and financing activity in the primary market and corporate R&D expenditure, with the rise of some innovative drugs and emerging therapies, the related CXO business has brought considerable incremental market to the industry.
-
The overall performance of the traditional Chinese medicine sector achieved high growth and ushered in greater investment opportunities
Time of Update: 2022-05-14
Among them, the overall performance of the traditional Chinese medicine sector has also achieved high growth, with 30 traditional Chinese medicine companies having a net profit of more than 100 million yuan .
-
Jiangxi Province has determined the time for the sixth batch of national procurement bids!
Time of Update: 2022-05-13
On May 5, the Jiangxi Provincial Medical Insurance Bureau issued the "Notice on the Implementation of the Selection Results of the Sixth Batch of Nationally Organized Centralized Drug Procurement (Insulin Special)", announcing that from 0:00 on May 25, 2022, medical institutions in the province will begin After the selection result is executed, it is now possible to log in to the recruitment platform to establish a distribution relationship and sign a tripartite agreement .
-
3 pharmaceutical companies were approved on the same day Yuandong, Huiyu... 1.5 billion injections
Time of Update: 2022-05-13
A few days ago, the official website of the State Food and Drug Administration showed that the concentrated solution of sodium valproate for injection was approved by Chengdu Yuandong Biopharmaceutical, Sichuan Huiyu Pharmaceutical, and Chengdu Lier Pharmaceutical on the same day.
-
National Medical Insurance Bureau: The coverage of cross-provincial direct settlement of outpatient expenses is further expanded
Time of Update: 2022-05-13
Previously, the "Opinions on the Implementation of the "Government Work Report" on the Division of Key Work issued by the State Council made it clear that in 2022, it is necessary to continue to promote and improve the direct settlement method across provinces, and to introduce relevant policies before the end of June this year .
-
The pharmaceutical industry is blowing "cross-border" wind, and big health has become the focus of layout
Time of Update: 2022-05-13
Therefore, Huahai Pharmaceutical has launched the first brand of the big health sector - "freeze-drying" at the node of the current market consumption upgrading and transformation .
For example, in 2021, the "Zhenyinzi" tea brand under the traditional pharmaceutical company North China Pharmaceutical announced that it will soon start attracting investment .
-
Traditional Chinese medicine formula granules will achieve good growth in the future, and many companies will enter the market
Time of Update: 2022-05-13
China Traditional Chinese Medicine stated in the announcement that its turnover growth was mainly due to the obvious advantages of quality controllability and convenience of traditional Chinese medicine formula granules, as well as effective academic promotion, and the market recognition continued to improve, promoting the steady development of the business .
-
Clinical approval for Omicron Aibo Biotech's new coronavirus mRNA vaccine in the United Arab Emirates
Time of Update: 2022-05-13
For the Austrian strain, Aibo Biosciences will start the development of mRNA vaccines at the end of November 2021, and it will take only 32 days to complete the design of mRNA sequences to obtain preliminary immunogenicity data in mice .
The company has obtained the "Drug Production License" for the new crown mRNA vaccine in November 2021 .
-
The State Food and Drug Administration issued the "Guidelines for Pharmacovigilance Inspection"
Time of Update: 2022-05-13
3. All provincial drug supervision and administration departments should incorporate the relevant content of pharmacovigilance inspection in their daily supervision work in light of the supervision actuality of their respective administrative regions, formulate inspection plans scientifically, organize their implementation in an orderly and efficient manner, and further refine the relevant work content, Improve relevant work requirements and effectively implement territorial supervision responsibilities .
-
16.3 billion anti-allergic drug market business opportunities are "sensitive"
Time of Update: 2022-05-13
Yangtze River Pharmaceutical ranks first From the perspective of enterprises, there are 181 manufacturers selling anti-allergic drugs in the sample hospitals in 2021, of which the sales of Yangzijiang Pharmaceutical Group (including 4 subsidiaries) accounted for 29.
-
China's insulin centralized procurement implements "high quality and reasonable price" drugs to benefit a large number of diabetic patients
Time of Update: 2022-05-13
(Finish) The Office of the National Medical Insurance Administration and the General Office of the National Health and Health Commission issued the "Notice on Improving the Supporting Measures for the Centralized Procurement and Use of Nationally Organized Drugs (Insulin Special)" .
-
Domestic new crown mRNA vaccine: CanSino starts clinical
Time of Update: 2022-05-13
On May 5, CanSino registered to start the Phase I clinical trial of the new crown mRNA vaccine, targeting adults aged 18 and over, with the trial registration number: CTR20221057 .
cn/v5/home/)Domestic companies have already invested in the development of new crown mRNA vaccines .
-
The latest appointment of Hengrui Medicine: Dai Hongbin, former deputy general manager, was promoted to general manager
Time of Update: 2022-05-13
At the same time, the senior management team also welcomes "new forces" Not long ago, Hengrui Pharmaceutical announced that Zhang Xiaojing was appointed as Deputy General Manager and Chief Medical Officer (Oncology), and Wang Quanren was appointed as Deputy General Manager.
-
The next-generation PDE4 inhibitor introduced by Cinda exceeds 200 million US dollars to apply for clinical application in China
Time of Update: 2022-05-13
Compared to other PDE4 inhibitors, orismilast's high selectivity for PDE4 isoforms B and D and the excellent therapeutic window brought by the innovative sustained-release approach is expected to lead to better anti-inflammatory efficacy and tolerability .
-
Tapentadol, a subsidiary of Renfu Pharmaceutical Holdings, obtained the tentative approval number of the US FDA
Time of Update: 2022-05-13
(referred to as "Yichang Humanwell Pharmaceutical US Company") received the tentative approval number for tapentadol from the US FDA.
After the above patents expire and are officially approved, Yichang Renfu Pharmaceutical US Company can market the tapentadulo tablets that have obtained the ANDA approval number this time .
-
The top list of pharmaceutical companies' revenue is released!
Time of Update: 2022-05-13
AstraZeneca's revenue growth was mainly driven by last year's $39 billion acquisition of Alexion and the new crown vaccine Vaxzevria .
-
Unexplained hepatitis in many countries may exacerbate the supply of raw materials such as Huang Baiyin Chen!
Time of Update: 2022-05-13
Compared with the public's concern about acute hepatitis cases in children with unknown causes, our platform is more concerned about the supply of raw materials of traditional Chinese medicines commonly used in hepatitis, such as Yin Chen and Tian Jihuang .
-
Drug sampling in many places failed!
Time of Update: 2022-05-13
At present, the Hubei Provincial Drug Administration has instructed relevant departments to take necessary control measures such as sealing up, detaining, suspending sales, and recalling drugs that do not meet the requirements, and investigate and punish the production enterprises and sampled units in accordance with relevant laws and regulations .
-
Novartis suspends production of two radioligand drugs due to potential quality issues
Time of Update: 2022-05-13
CompilenewbornNovartis announced on Thursday that it has suspended production of neuroendocrine tumor treatment Lutathera and recently FDA-approved prostate cancer treatment Pluvicto at its plants in Ivrea, Italy and Milburn, New Jersey .
Novartis halts US production of radioligand cancer therapies, citing potential quality issues2.
-
Publish documents in multiple places to dynamically adjust the "dual-channel" management catalog of medical insurance
Time of Update: 2022-05-13
On April 20, 2022, the Jiangsu Medical Insurance Bureau issued a document to dynamically adjust the "dual-channel" management and separate payment list according to the results of the dynamic adjustment of the National Drug List .
